title: [Physostigmine in treatment of cerebellar ataxia].
abstract: Cerebellar ataxias are still a challenging problem for neurologists, and to this day there exists no medical, physiotherapeutic, psychot-erapeutic or surgical therapy which constantly leads to a reduction of ataxic symptoms. In the pathophysiology of cerebellar ataxia a cholinergic defect has often been described. In a double-blind, cross-over study with 14 patients with cerebellar ataxia and an open follow-up, long-term study with 21 patients, the clinical effects of physostigmine capsules in doses up to 10 mg per day were studied. Moreover, a transdermal application (physostigmine patch) was developed, achieving constant physostigmine plasma levels for 24 h. Of 14 patients treated with physostigmine during the double-blind, cross-over study, nine could correctly distinguish between verum and placebo. They all showed small but constant improvements, clearly experienced by the patients. With the physostigmine patch, 12 of 14 patients improved. Thirteen of 14 patients decided to take part in open follow-up studies with physostigmine, and most of them preferred the physostigmine patch as long-term medication. To date, 21 patients with cerebellar ataxia have been treated with physostigmine. As far as we can judge at the end of a treatment period of at least 2 years, the progression of the disease could be stopped in 17 of 21 patients. These patients reported small but constant effects, and none wants to live without the physostigmine patch.
authors.affiliation: Neurologische Poliklinik, Universität, Ulm.
authors.forename: J C
authors.initials: JC
authors.lastname: Aschoff
authors.forename: N A
authors.initials: NA
authors.lastname: Kailer
authors.forename: K
authors.initials: K
authors.lastname: Walter
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002524:Cerebellar Ataxia / Q000175:diagnosis / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005684:Gait / Q000187:drug effects; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D009849:Olivopontocerebellar Atrophies / Q000175:diagnosis / Q000188:drug therapy*; D010830:Physostigmine / Q000008:administration & dosage* / Q000009:adverse effects; D013132:Spinocerebellar Degenerations / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D010830:Physostigmine
vernacular_title: Physostigmin in der Behandlung von Kleinhirnataxien.